This Düsseldorf IP boutique cannot be ignored. Hardly any other patent attorney firm advises at such a consistently high level across all technical fields as Cohausz & Florack. Competitors shower the firm with praise, calling it “very high quality” and “well-versed on the opposing side”. Cohausz & Florack never loses sight of extensive and complex proceedings regarding mobile communications standards and pharmaceuticals.
The firm’s biggest success to date is the representation of core client Bayer in a Europe-wide dispute over the blockbuster drug Xarelto. The team led by renowned pharmaceutical experts Natalie Kirchhofer and Arwed Burrichter succeeded in reinstating a dosage patent for the active ingredient rivaroxaban before the EPO Board of Appeal – a key commercial success for Bayer. The protection provided by this dosage patent brings the company, which is currently being restructured, billions in sales and thus time to invest in new products. The Cohausz & Florack attorneys played a significant role in the Europe-wide strategy of keeping generic manufacturers out of the markets by means of preliminary injunctions.
The firm is also involved in high-profile mobile communications cases, for example for Nokia. The team led by SEP expert Christoph Walke now also represents Nokia at the UPC.
The firm is as forward-thinking in its clients’ patent strategy as it is in developing its own talent. It continuously promotes young talent, which one competitor praises as a “great young generation”. Younger partners such as Matthias Waters are already enjoying market visibility, for example in work for Sharp, Palmira, Wireless and DHL.